Zenocutuzumab - CISMeF

Preferred Label : Zenocutuzumab;

NCIt synonyms : Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128; Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128;

NCIt definition : A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.;

UNII : AE72RB1W1X;

CAS number : 1969309-56-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1969309-56-5 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : MCLA 128; MCLA-128;

NCI Metathesaurus CUI : CL554279;

Details

Origin ID

C152948;

UMLS CUI

C4726984;

Automatic exact mappings (from CISMeF team)
- zenocutuzumab [MeSH concept]
Currated CISMeF NLP mapping
- zenocutuzumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- zenocutuzumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]
- Receptor Tyrosine-Protein Kinase erbB-3 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients